AstraZeneca's (AZN) Lynparza Gets FDA Nod In 1st Line Setting
Zacks Investment Research | Dec 20, 2018 05:34AM ET
AstraZeneca Plc. (NYSE:AZN) and partner Merck & Co., Inc. (NYSE:MRK) announced that the FDA has approved a label expansion of its advanced ovarian cancer drug Lynparza. The FDA has approved Lynparza as a first-line maintenance therapy for BRCA-mutated advanced ovarian cancer. It is the first regulatory approval for a PARP inhibitor in first-line maintenance setting.
We note that Lynparza is already marketed in the United States for platinum-sensitive relapsed ovarian cancer, regardless of BRCA status and germline BRCAm HER2-negative metastatic breast cancer.
The approval in the first-line setting was based on data from the pivotal phase III SOLO-1 study, which demonstrated that Lynparza (olaparib) tablets led to a statistically-significant and clinically-meaningful improvement in progression free survival (PFS) compared to placebo in women with BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy.
In the Lynparza arm, 60% of the patients were progression free at 36 months compared with 27% in the placebo arm. Lynparza reduced the risk of disease progression or death by 70% compared to placebo, following response to platinum-based chemotherapy.
With the approval for expanded use in the first-line setting, sales of Lynparza can improve in the future quarters.
Other PARP inhibitors available in the market are Tesaro, Inc.’s (NASDAQ:TSRO) Zejula and Clovis Oncology, Inc.’s (NASDAQ:CLVS) Rubraca. Zejula and Rubraca are also being evaluated in late-stage studies in the first-line maintenance setting for the treatment of ovarian cancer patients who have responded to platinum-based chemotherapy.
This year so far, AstraZeneca’s shares have risen 13.7% compared with the industry ’s growth of 4.9%.
In a separate press release, AstraZeneca and Merck announced positive results from phase III SOLO-3 study of Lynparza, which was conducted as a post-approval commitment in agreement with the FDA. The results showed that BRCAm advanced ovarian cancer patients treated with Lynparza following two or more prior lines of chemotherapy experienced a statistically-significant and clinically-meaningful improvement in the primary endpoint of objective response rate (ORR) and the key secondary endpoint of progression-free survival (PFS) compared to chemotherapy. This is the fourth phase III study to report positive results for Lynparza. The companies plan to discuss the results with the FDA.
Get The News You Want
Astrazenca also announced that two phase III studies OLYMPUS and ROCKIES, evaluating pipeline candidate roxadustat for the treatment of patients with anaemia in chronic kidney disease (CKD), met their primary efficacy endpoint.
The OLYMPUS study was conducted on non-dialysis-dependent CKD patients, while the ROCKIES study was conducted on dialysis-dependent CKD patients.
While OLYMPUS demonstrated a statistically-significant and clinically-meaningful improvement in haemoglobin versus placebo, ROCKIES showed a similar improvement in haemoglobin versus epoetin alfa.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is being jointly developed and commercialized by AstraZeneca and FibroGen.
Data from the phase III OLYMPUS and ROCKIES trials together with the efficacy and pooled safety data from the global phase III program conducted by AstraZeneca, FibroGen and Astellas will be part of the regulatory submission package in the United States and other major countries.
We remind investors that roxadustat was approved in China (its first regulatory approval) for the treatment of anaemia in chronic kidney disease patients on dialysis, earlier this week.
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.